Medical sovereignty: Malaysia should not automatically accept US FDA approvals


Malaysia's National Pharmaceutical Regulatory Agency (NPRA) has been working hard towards achieving WHO’s stringent Listed Authority status, leveraging its status as a WHO Collaborating Centre for Regulatory Control of Pharmaceuticals to reach the highest global standards of regulatory practice for approving medical products.

Although Malaysia allows for expedited regulatory review for pharmaceutical products previously approved by leading regulatory authorities in the US, EU, Australia, Canada, Japan, Switzerland, the UK, and Asean, it has always protected its own supplemental due diligence review of safety, efficacy, and assured quality and its own right to inspect pharmaceutical facilities.

Get 20% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Columnists

So much to do, with little time
Pet ownership must not burden neighbours
When knowledge has no heirs
Green wave has become a Malay tsunami
A cut above? Circumcision and cancer risk
Can silat parry the puppeteer’s strings?
Reality of Malaysia’s changing demographics
Affordability, not culture wars
Keep the lamp lit for Malaysian football despite dark episodes
Has Anthony Loke resigned or not?

Air Pollutant Index

Note: API is calculated based on 24hr running average of the most dominant parameter.

Highest API Readings

    Select State and Location to view the latest API reading

    Others Also Read